Literature DB >> 16982960

Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure.

Xian Wu Cheng1, Koji Obata, Masafumi Kuzuya, Hideo Izawa, Kae Nakamura, Eri Asai, Tetsuro Nagasaka, Masako Saka, Takahiro Kimata, Akiko Noda, Kohzo Nagata, Hai Jin, Guo-Ping Shi, Akihisa Iguchi, Toyoaki Murohara, Mitsuhiro Yokota.   

Abstract

Cathepsins are cysteine proteases that participate in various types of tissue remodeling. However, their expressions during myocardial remodeling have not been examined. In this study, we investigated their expressions in the left ventricular (LV) myocardium of rats and humans with hypertension-induced LV hypertrophy or heart failure (HF). Real-time PCR and immunoblot analysis revealed that the abundance of cathepsin S mRNA or protein in the LV tissues was greater in rats or humans with HF than in those with hypertrophy or in control subjects. Immunostaining showed that cathepsin S was localized predominantly to cardiac myocytes and coronary vascular smooth muscle cells, but also overlapped in part with macrophages. Elastic lamina fragmentations significantly increased in the LV intramyocardial coronary arteries of HF rats. The amount of elastolytic activity in the extract of the LV myocardium was markedly increased for HF rats compared with controls, and this activity was mostly because of cathepsin S. Although the amount of elastin mRNA was increased in the LV myocardium of HF rats, the area of interstitial elastin was not. The expression of interleukin 1beta was increased in the LV myocardium of HF rats, and this cytokine was found to increase the expression and activity of cathepsin S in cultured neonatal cardiomyocytes. These results suggest that cathepsin S participates in pathological LV remodeling associated with hypertension-induced HF. This protease is, thus, a potential target for therapeutics aimed at preventing or reversing cardiac remodeling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16982960     DOI: 10.1161/01.HYP.0000242331.99369.2f

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  35 in total

Review 1.  Specialized roles for cysteine cathepsins in health and disease.

Authors:  Jochen Reiser; Brian Adair; Thomas Reinheckel
Journal:  J Clin Invest       Date:  2010-10-01       Impact factor: 14.808

2.  Cathepsins in heart disease-chewing on the heartache?

Authors:  Jordan Blondelle; Stephan Lange; Barry H Greenberg; Randy T Cowling
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-06       Impact factor: 4.733

Review 3.  Role of various proteases in cardiac remodeling and progression of heart failure.

Authors:  Alison L Müller; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2012-05       Impact factor: 4.214

Review 4.  Cysteinyl cathepsins in cardiovascular diseases.

Authors:  Xian Zhang; Songyuan Luo; Minjie Wang; Guo-Ping Shi
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-01-09       Impact factor: 3.036

5.  Mast cell-deficiency protects mice from streptozotocin-induced diabetic cardiomyopathy.

Authors:  Aina He; Wenqian Fang; Kun Zhao; Yajun Wang; Jie Li; Chongzhe Yang; Feriel Benadjaoud; Guo-Ping Shi
Journal:  Transl Res       Date:  2019-01-19       Impact factor: 7.012

6.  Myocardial and Serum Galectin-3 Expression Dynamics Marks Post-Myocardial Infarction Cardiac Remodelling.

Authors:  Umesh C Sharma; Wassim Mosleh; Milind R Chaudhari; Rujuta Katkar; Brian Weil; Chris Evelo; Thomas R Cimato; Saraswati Pokharel; W Matthijs Blankesteijn; Gen Suzuki
Journal:  Heart Lung Circ       Date:  2016-12-19       Impact factor: 2.975

Review 7.  Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.

Authors:  Yinan Hua; Sreejayan Nair
Journal:  Biochim Biophys Acta       Date:  2014-05-09

8.  Role of cathepsin D activation in major adverse cardiovascular events and new-onset heart failure after STEMI.

Authors:  Aylin Hatice Yamac; Emrah Sevgili; Sitki Kucukbuzcu; Muharrem Nasifov; Ziya Ismailoglu; Elif Kilic; Cilem Ercan; Parviz Jafarov; Hüseyin Uyarel; Ahmet Bacaksiz
Journal:  Herz       Date:  2015-04-25       Impact factor: 1.443

9.  Cathepsin K knockout alleviates pressure overload-induced cardiac hypertrophy.

Authors:  Yinan Hua; Xihui Xu; Guo-Ping Shi; Adam J Chicco; Jun Ren; Sreejayan Nair
Journal:  Hypertension       Date:  2013-03-25       Impact factor: 10.190

10.  Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment.

Authors:  Xian Wu Cheng; Toyoaki Murohara; Masafumi Kuzuya; Hideo Izawa; Takeshi Sasaki; Koji Obata; Kohzo Nagata; Takao Nishizawa; Masakazu Kobayashi; Takashi Yamada; Weon Kim; Kohji Sato; Guo-Ping Shi; Kenji Okumura; Mitsuhiro Yokota
Journal:  Am J Pathol       Date:  2008-06-26       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.